U.S. Congress legislation · 119th Congress
HR1285: Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Status: In committee, May 14, 2026
What the bill says
From the introduced text, May 14, 2026:
IV 119th CONGRESS 2d Session H. RES. 1285 IN THE HOUSE OF REPRESENTATIVES May 14, 2026 Ms. DeGette (for herself, Ms. Pressley , Ms. McClellan , Ms. Clark of Massachusetts , Mr. Bell , Mr. Tonko , Mr. García of Illinois , Ms. Velázquez , Mr. Moulton , Ms. Pettersen , Ms. Norton , Ms. Balint , and Ms. Dexter ) submitted the following resolution; which was referred to the Committee on Energy and Commerce RESOLUTION Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. Whereas Congress, by enacting the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq. ), authorized the Food and Drug Administration (in this preamble referred to as the FDA ) to determine, based on the scientific evidence, whether a drug is safe and effective for the intended use of the drug; Whereas Congress authorized the FDA to impose or maintain a Risk Evaluation and Mitigation Strategy (in this preamble referred to as REMS ) for a drug only where necessary to ensure …
Sponsors
- Diana DeGette (D, HD-001) · primary sponsor
- Ayanna Pressley (D, HD-007)
- Jennifer McClellan (D, HD-004)
- Katherine Clark (D, HD-005)
- Wesley Bell (D, HD-001)
- Paul Tonko (D, HD-020)
- Jesus Garcia (D, HD-IL-4)
- Nydia Velazquez (D, HD-NY-7)
- Seth Moulton (D, HD-006)
- Brittany Pettersen (D, HD-007)
- Norton, Eleanor (D, HD-000)
- Balint, Becca (D, HD-000)
Latest actions
- : Referred to the House Committee on Energy and Commerce.
- : Submitted in House
Subjects: Health
Common questions
- What is HR1285?
- HR1285 is a bill in Congress (119th Congress): Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
- What is the status of HR1285?
- In committee as of May 14, 2026. Latest action: Referred to the House Committee on Energy and Commerce. (May 14, 2026).
- Who sponsored HR1285?
- Diana DeGette (D, HD-001), with 11 co-sponsors.
- Where is the official record for HR1285?
- On the Congress website: https://www.congress.gov/bill/119th-congress/house-res/1285
Source: official Congress record. Tracked by Delilah, AI for legislation across all 50 states and Congress.